Key Takeaways
- Soft quarter, tariff drag: Revenue grew 6.7% YoY to Rs. 1,988 crores, but the bottom line absorbed a ~60-day hit from US tariffs before customers agreed to pass-throughs. Normalization is expected from Q2.
- Cost reset underway: A cost optimization program launched in Q2 targets Rs. 40-50 crores in annual savings, with the Bhavnagar facility shutdown alone saving Rs. 20 crores. An analyst's math puts total savings closer to Rs. 50-60 crores.
- The pivot to own and licensed brands: Owned brands grew 14% YoY and licensed brands 29%, while the low-margin Middle East gold business was discontinued. Management is deliberately replacing low-quality revenue with double-digit-margin streams.
- Lab-grown diamonds are taking over: Lab-grown was ~30% of FY25 revenue and is expected to become the majority of the business over the next two years as natural diamond SKUs transition.
- What to watch next quarter: Whether tariff pass-throughs are fully completed by end of Q1 as promised, the pace of D2C growth toward the 40-50% target, and any signs of Irasva's unit economics improving enough to justify expansion.
Tariff Impact & Mitigation
- The 60-day hit: An additional 10% US tariff on jewelry landed without contractual pass-through clauses, so the company absorbed the cost for 45-60 days while renegotiating with customers. Revenue was not meaningfully affected, but the bottom line took a hit for that window.
- Resolution status: Most customers have now agreed to accept the tariff increase, with some still pending. Full resolution is expected by end of Q1 FY26, and price increases have already been taken. Margins should normalize from Q2 onwards.
- Demand holding: No impact on demand has been seen yet, with US consumer demand described as resilient.
- The China opportunity: In the last two months, 4-5 new customers were added as brands and retailers look to move supply chains away from China. Management sees a "very big opportunity" for Indian companies if differential tariffs persist.
- UAE backup plan: If reciprocal tariffs escalate, the company has a contingency to manufacture goods in the UAE, though this remains a backup option for now.
Sumit Shah: "if there are differential tariffs between India and China, we see a very big opportunity to actually not just for us, for other companies in India to take market share."
Segment Performance & Revenue Quality
- Owned brands momentum: Grew 14% YoY overall, with US brands up 18%. D2C is expected to grow 40-50% in the current year, driven by higher average order values and the shift to lab-grown diamonds.
- Licensed brands surge: Grew 29% YoY on steady orders from retail partners and D2C channels. Low double-digit growth is expected going forward.
- Customer brands steady: Contributed Rs. 375 crores at an 8.2% EBITDA margin. Growth is expected to be mid-single digits, reflecting the segment's mature profile.
- The revenue quality story: Top-line stagnation is deliberate. The company discontinued a ~Rs. 700 crore low-margin Middle East gold business and replaced it with ~Rs. 700 crore in new licensed and own-brand revenue over 4-5 years. The focus is on revenue that delivers returns above the cost of capital, not top-line growth for its own sake.
- Irasva losses: The India retail brand lost ~Rs. 4 crores last year because corporate overhead is not yet amortized over enough stores. Expansion is paused until unit economics show signs of profitability.
Sumit Shah: "we are much more focused on quality of revenue and revenue that will deliver high ROE and ROCE and not just revenue that will deliver returns that are below cost of capital."
Cost Optimization & Balance Sheet
- Program scope: Launched toward the end of Q2 FY25, the cost optimization program targets Rs. 40-50 crores in annual savings. Per an analyst's math, total savings including the Bhavnagar shutdown are closer to Rs. 50-60 crores.
- Bhavnagar facility: Shut down entirely on April 15, 2025. The closure saves Rs. 20 crores annually and reflects a structural shift: as average order values rise and the mix moves toward lab-grown diamonds, the company simply needs less production capacity. No revenue reduction is anticipated.
- Land sale timeline: Debonding with customs and clearing inventory will take 3-6 months, after which the land and building (owned by the company) will be put on the market. Proceeds will pay down bank debt. No value estimate is available yet.
- Balance sheet improvement: Net debt fell to Rs. 250 crores from Rs. 319 crores, with net debt to equity improving to 0.18 from 0.28. Cash and investments rose by Rs. 75 crores to Rs. 265 crores.
- Q1 FY26 expense: Some restructuring expense related to the Bhavnagar shutdown is expected in Q1. Separately, Q4 included Rs. 3 crores in acquisition-related expenses for Jean Dousset, not restructuring costs.
Sumit Shah: "I think that structurally as we move to a more higher value-added product because of direct-to-consumer, higher average order value and shift towards lab grown diamonds, the fundamental need for our company in terms of production capacity has gone down because our average order value has increased meaningfully."
Lab-Grown Diamond Transition
- Current share: Lab-grown diamonds were approximately 30% of FY25 revenue, though management did not have the exact figure at hand during the call.
- The trajectory: Lab-grown is fully expected to become the majority of the business over the next two years as older natural diamond SKUs transition to newer lab-grown SKUs.
- Structural driver: The shift toward lab-grown diamonds is one of the key reasons production capacity needs have declined, alongside higher average order values and the D2C pivot.
Brands & Retail Expansion
- Jean Dousset acquisition: A strategic investment in a US-based jewelry designer known for bespoke lab-grown diamonds and bridal jewelry, with a flagship store in Hollywood and a strong digital presence. A New York flagship is planned for Q3 of the current financial year.
- Wonder Fine Jewelry: A new umbrella brand launched, encompassing Star Wars, Disney, Jewels and Marvel, aiming to integrate all IP-led brands onto one platform.
- Irasva celebrity line: Working toward launching a line with a celebrity in Q3 of the current year, though broader retail expansion remains on hold.
- Jean Dousset wholesale: Not yet at the point of expanding distribution to retail partners, though management may consider it as the brand scales. No conversations are currently ongoing.
Sumit Shah: "I think any expansion in retail without the unit economics being fixed will result in losses. I think one can't hurry into retail expansion because it's a high fixed cost business."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Tariff resolution | Full pass-through agreement with all customers | End of Q1 FY26 |
| Margin normalization | Margins to recover after Q1 tariff drag | From Q2 FY26 onwards |
| D2C revenue growth | Top-line growth of 40-50% in direct-to-consumer segment | FY26 |
| Licensed brands growth | Low double-digit growth | FY26 |
| Customer brands growth | Mid-single-digit growth | FY26 |
| Cost savings | Rs. 50-60 crores in annual savings from optimization program (per analyst's math, endorsed by management) | Ongoing |
| Bhavnagar land sale | Land and building put on market after debonding and inventory clearance | 3-6 months for clearance, then sale over 1-2 years |
| Net debt zero | Achieve zero net-debt status | 12-24 months |
| Capital return to shareholders | Buyback or dividend becomes a priority | Post achieving zero net debt |
| Jean Dousset New York store | Flagship store opening | Q3 FY26 |
| Irasva celebrity line | Launch of celebrity collaboration | Q3 FY26 |
| Lab-grown diamond share | Lab-grown becomes majority of business | Over next 2 years |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue from continuing operations | ₹514 cr, +7% YoY |
| Owned brands revenue | ₹55 cr, +14% YoY |
| US owned brands revenue | ₹50 cr, +18% YoY |
| Licensed brands revenue | ₹84 cr, +29% YoY |
| Licensed brands EBITDA margin | 13.4% |
| Customer brands revenue | ₹375 cr, EBITDA margin 8.2% |
| Adjusted PAT | ₹23 cr, +7.4% YoY; margin 4.4% vs 3.9% in Q4 FY24 |
| FY25 revenue from continuing operations | ₹1,988 cr, +6.7% YoY |
| FY25 adjusted EBITDA | ₹191 cr, +24% YoY; margin 9.6% vs 8.3% in FY24 |
| FY25 adjusted PAT | ₹89 cr, +21.5% YoY; margin 4.3% vs 3.5% in FY24 |
| Net debt | ₹251 cr, down from ₹319 cr in FY24 |
| Net debt to equity | 0.18, vs 0.28 a year ago |
| Cash and bank balances with current investments | ₹265 cr, up ₹75 cr from March 31, 2024 |
| Cost optimization annual savings target | ₹50–60 cr, visible from Q2 FY26 |
| D2C segment growth guidance (FY26) | 40–50% |
| Licensed brands growth guidance (FY26) | Low double digits |
| Customer brands growth guidance (FY26) | Mid-single digits |
| Tariff impact on Q1 FY26 EBITDA | ~₹10 cr, from 60-day absorption of US tariffs |
| Lab-grown diamond share of FY25 revenue | ~30% (management estimate) |
| US share of total revenue | 65% |
| Jean Dousset LA store annual sales | ~₹25 cr |
| Irasva FY25 loss | ~₹4 cr |
| Interest cost YoY change | -16% YoY in Q4 FY25 |